These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35105150)

  • 1. Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration.
    Madero Velázquez L; Muñoz Pérez R; Rodríguez A; Bernal L; Orts B; Sempere L; Gutiérrez Casbas A
    Rev Esp Enferm Dig; 2022 Jun; 114(6):358. PubMed ID: 35105150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy.
    Sangrós Sahún MJ; Goñi Gironés E; Camarero Salazar A; Estébanez Estébanez C; Lozano Martínez ME
    Rev Esp Med Nucl Imagen Mol; 2016; 35(6):391-393. PubMed ID: 27246291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.
    Amarnani R; Travis S; Javaid MK
    Rheumatology (Oxford); 2020 Aug; 59(8):2166-2168. PubMed ID: 31930323
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series.
    Seng NW; Barco JB; Wong MH; Lim KX; Peh WM; Ng CT; Cushway T; Foo FJ; Koh FH
    Transfus Med; 2023 Dec; 33(6):503-508. PubMed ID: 37263781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory hypophosphatemia following ferric carboxymaltose administration.
    Efe O; García JDC; Mount DB; Sheridan AM
    CEN Case Rep; 2021 Nov; 10(4):473-475. PubMed ID: 33715107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferric carboxymaltose (Ferinject®) associated hypophosphataemia: case report illustrating the need for increased awareness to minimise incidence and risk.
    Fisher S; Jonker L
    Acute Med; 2020; 19(2):102-105. PubMed ID: 32840261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
    Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
    J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypophosphatemic osteomalacia induced by intravenous iron therapy: a case report.
    Samões B; Silva B; Martins A; Oliveira D; Rajão Martins F; Fonseca D; Costa L; Bernardes M
    Joint Bone Spine; 2023 Sep; 90(5):105586. PubMed ID: 37127260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorus levels in children treated with intravenous ferric carboxymaltose.
    Kirk SE; Scheurer ME; Bernhardt MB; Mahoney DH; Powers JM
    Am J Hematol; 2021 Jun; 96(6):E215-E218. PubMed ID: 33735470
    [No Abstract]   [Full Text] [Related]  

  • 16. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.
    Vilaca T; Velmurugan N; Smith C; Abrahamsen B; Eastell R
    J Bone Miner Res; 2022 Jun; 37(6):1188-1199. PubMed ID: 35426179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
    Sánchez González R; Ternavasio-de la Vega HG; Moralejo Alonso L; Inés Revuelta S; Fuertes Martín A
    Med Clin (Barc); 2015 Aug; 145(3):108-11. PubMed ID: 25579771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
    Schaefer B; Würtinger P; Finkenstedt A; Braithwaite V; Viveiros A; Effenberger M; Sulzbacher I; Moschen A; Griesmacher A; Tilg H; Vogel W; Zoller H
    PLoS One; 2016; 11(12):e0167146. PubMed ID: 27907058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status.
    Fang W; Kenny R; Rizvi QU; McMahon LP; Garg M
    BMC Gastroenterol; 2020 Jun; 20(1):183. PubMed ID: 32522150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
    Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
    Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.